DSIP (delta sleep-inducing peptide) is a research-only peptide with a sparse, dated evidence base and no approved labeling. The amounts below are commonly cited and anecdotal, not medically established. They are shown for education, not as a protocol. Any use should be discussed with a qualified clinician.
Overview
There is no validated DSIP dose, because there is no validated DSIP effect. The peptide's two double-blind human trials both concluded its sleep benefit was of little clinical significance (Bes et al. 1992; Monti et al. 1987), and no dose-finding work ever followed. What circulates instead is an informal community pattern, which this page reports as background — alongside the more revealing fact of what the actual studies used.
Common community pattern
The pattern most often repeated in community logs and vendor materials is:
- Roughly 100–300 mcg, given subcutaneously, at night ahead of bedtime.
- Used intermittently rather than every night in many accounts.
- Starting toward the low end is the cautious framing given how little data exists.
These are anecdotal figures with weak supporting evidence, not a validated dose. There is no established therapeutic range, and no published study has tested this subcutaneous nightly pattern at all.
What the studies actually used
The comparison worth knowing: both human insomnia trials gave DSIP intravenously at 25 nmol per kg of body weight (PMID 1299794; PMID 3583493). With DSIP's molecular weight of about 849, that works out to roughly 21 mcg/kg — on the order of 1.5 mg for a 70 kg adult, several times the community's typical total, and delivered directly into a vein rather than under the skin. Even at that exposure, by that route, the measured benefit was marginal.
The early literature adds a second complication: a U-shaped dose-response curve, for both dose and infusion timing, was reported in the original animal and human work (Graf & Kastin, Neurosci Biobehav Rev 1984). In plain terms, more DSIP was not reliably more effective, and sometimes less was. A compound whose effect disappears at both ends of the dose range, tested by a route nobody uses today, offers no rational anchor for the numbers circulating online — the community range is not a scaled-down version of the studied dose; it is unrelated to it.
How it is administered
DSIP ships as a lyophilized powder reconstituted with bacteriostatic water, then injected under the skin.
- The final dose depends on reconstitution — the water volume sets concentration, and the amount drawn is read as syringe units. The Peptide Calculator maps this arithmetic.
- For an old, niche, unregulated peptide, identity and purity can vary considerably between suppliers, which undermines even careful math: a precisely measured dose of an unverified powder is precision applied to an unknown.
Why oversight matters
DSIP's dosing question is unusual: the standard experimental-peptide caveat is "no human data," but here the human data exist and are discouraging. Arithmetic precision cannot create certainty where the underlying science found little effect at any dose. A clinician can evaluate sleep problems properly — most of which have evidence-based treatments — and weigh whether an unvalidated peptide has any place in that picture. Treat the pattern above as a description of what circulates online, not as instruction.